Mylan launches UK insulin glargine rival
Mylan has launched in the UK the Semglee (insulin glargine) biosimilar that it developed with Biocon. Available in 100 units/ml pre-filled pens, the once-a-day long-acting basal insulin is indicated to treat diabetes mellitus in adults and children above two years of age.
You may also be interested in...
Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.
Immediately upon reimbursement listing, Mylan has launched in Australia the insulin glargine biosimilar that it co-developed with India’s Biocon.
As part of feedback on the future of insulin biosimilars in the wake of FDA guidance over transitioning insulins to biologic status, the agency has been urged to deem all biosimilar insulins interchangeable as well as to push back against originator attempts to shield individual product ‘ecosystems’ from competition.